Focus on Saxenda® solution for injection

  • L Lambert Amayeza Information Services
Keywords: Saxenda®, obesity

Abstract

The World Obesity Federation recognises obesity as a “chronic relapsing disease process”, defined as having a body mass index (BMI) equal to or greater than 30 kg/m2 and has been identified as a strong predictor of cardiovascular disease.1,2 The challenge with weight loss is keeping it off because of changes in appetite-regulating hormones that occur after weight has been lost, leading to increased hunger and decreased satiety.2

Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue which, by virtue of its mechanism of action, increases satiety and decreases hunger, leading to weight loss.3

Author Biography

L Lambert, Amayeza Information Services

Amayeza Information Services, South Africa

Published
2021-03-26
Section
Product Focus